Thromb Haemost 1989; 61(02): 294-297
DOI: 10.1055/s-0038-1646579
Original Article
Schattauer GmbH Stuttgart

Heparin Inhibition of Endotoxin-Dependent Limulus Amebocyte Lysate Coagulation[*]

James A Marcum
The Marine Biological Laboratory Woods Hole, MA; the Department of Pathology, Harvard Medical School, Boston, MA; the Department of Biology, MIT, Cambridge, MA; and the Departments of Laboratory Medicine and Medicine, University of California School of Medicine, San Francisco, CA, USA
,
Jack Levin
The Marine Biological Laboratory Woods Hole, MA; the Department of Pathology, Harvard Medical School, Boston, MA; the Department of Biology, MIT, Cambridge, MA; and the Departments of Laboratory Medicine and Medicine, University of California School of Medicine, San Francisco, CA, USA
› Author Affiliations
Further Information

Publication History

Received 11 November 1988

Accepted after revision 18 November 1988

Publication Date:
30 June 2018 (online)

Preview

Summary

Addition of commercial heparin to preparations of the coagulation system obtained by hypotonic lysis of Limulus amebocytes, prior to the addition of endotoxin from gram-negative bacteria, inhibited gelation. Activation of the cell-lysate proclotting enzyme, utilizing a diluted lysate preparation and synthetic substrates, was inhibited to a comparable extent with either anticoagulantly active or inactive heparin. Other glycosaminoglycans, including heparan sulfate, dermatan sulfate, chondroitin 4-sulfate, and chondroitin 6-sulfate, did not inhibit the generation of clotting enzyme activity. Experiments conducted with preparations of proactivator(s) and proclotting enzyme, obtained by fractionation of lysate with heparin-Sepharose, revealed that inhibition of endotoxin-dependent activation of amebocyte lysate by heparin is mediated by precipitation of the proactivator(s) and can be prevented by increasing the salt concentration.

Supported, in part, by a Summer Fellowship (Marine Biological Laboratory, Woods Hole, MA) awarded to J.A.M.; Research Grants HL34800 and HL31035 from the National Heart, Lung, and Blood Institute, N. I. H., Bethesda, MD; and the Veterans Administration.